Nektar Therapeutics NKTR
-
New Morningstar Analyst Report - MannKind Corporation
… s hesitance to approve Afrezza has to do with its predecessor in the inhaled insulin class. Pfizer's PFE and Nektar's NKTR Exubera, the world's first inhaled insulin, was removed from the market in 2007 after the drug generated disappointing sales …
-
Nektar Therapeutics ( NKTR ): Q1 EPS of -$0.36 misses by $0.03. Revenue of $17.9M (+58% Y/Y). (PR)
Nektar Therapeutics ( NKTR ): Q1 EPS of -$0.36 misses by $0.03 . Revenue of $17.9M (+58% Y/Y). ( PR ) Post your comment!
-
5 Hedge Fund Biotech Stock Picks With Significant Short Covering
By Kapitall : Do you like to follow the buying trends of smart money investors? These investors include institutional investors such as hedge fund managers, and because of their experience and access to sophisticated research, their reported stock purchases are very interesting to the rest of the
-
Why The Markets Continue To Coalesce Around New Approaches To Treating Cancer
By Brett Korsgaard : The treatment of various forms of cancer is capturing significant media and investor interest. An article featured in last week's The Economist magazine regarding cancer treatment, the well received IPO of Verastem ( VSTM ) and the IPO registration for Stemline Theraeutics have
-
Long Undervalued, Is Alkermes Still A Bargain?
… in exchange for modest royalties, perhaps that's not so surprising. After all, other drug development names like Nektar ( NKTR ), PDL BioPharma ( PDLI ), and Flamel ( FLML ) really haven't worked out to early expectations. Things are different now …
-
Small-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
By Ganaxi Small Cap Movers : The biotech group as represented by the NYSE ARCA Biotech Index ($BTK) has been strong this year, now up over 27% YTD, and still trending higher. With both the market and the biotech sector in strong bull mode, now maybe an opportune time to go 'shop' for biotech ...
-
20 Biotech Stocks Being Bought Up By Hedge Funds
By Kapitall : The biotech industry is considered a growth industry with a very unique set of risks, mainly concerning the ability for research to turn into commercial success. For ideas on how to analyze stocks in the industry, we ran a screen. We screened the biotech industry for stocks seeing ...
-
The Age Of Personalized Medicine Has Arrived
By Randy Burd : Personalized Medicine, or PM, is a large umbrella term describing the use of patient information, usually genetic or biological, to tailor medical treatments that are specific to the characteristics of each individual. In 2009 an in-depth report by PricewaterhouseCoopers focused on
-
Nektar Therapeutics ( NKTR ): Q4 EPS of -$0.33 beats by $0.14. Revenue of $15.8M (-65% Y/Y) beats by $3M. Shares +1.9% AH. (PR)
Nektar Therapeutics ( NKTR ): Q4 EPS of -$0.33 beats by $0.14 . Revenue of $15.8M (-65% Y/Y) beats by $3M . Shares +1.9% AH. ( PR ) Post your comment!
-
Nektar Therapeutics sells royalties for $124 mln
(Reuters) - Nektar Therapeutics said it agreed to sell its future royalties on two drugs to Royalty Pharma for $124 million, to help repay debt.